President Donald Trump on Feb. 5 unveiled TrumpRx.gov, a new federal-backed website aimed at lowering prescription drug costs by steering consumers toward discounted cash prices rather than insurance-based coverage. The initiative, announced at the White House, positions itself as a rapid-response alternative to broader health-care reform, promising immediate savings on roughly 40 commonly prescribed medications.
Speaking at the event, Trump called the platform "one of the most transformative health care initiatives," arguing it would give Americans faster access to lower drug prices without navigating insurance formularies. TrumpRx does not sell medications directly but redirects users to participating pharmacies or manufacturers where discounted cash prices can be accessed.
The approach reflects a targeted strategy rather than a systemic overhaul. TrumpRx aggregates existing manufacturer and pharmacy discount programs into a single portal, allowing users to search drugs by name and retrieve coupons or purchase links. According to the site's frequently asked questions, the discounts apply only to cash-paying customers and cannot be combined with insurance benefits or credited toward deductibles.
Health policy experts say the model closely resembles existing discount platforms, most notably GoodRx. GoodRx confirmed it serves as a pricing integration partner for TrumpRx, with its discount codes accepted at more than 70,000 retail and mail-order pharmacies nationwide. Analysts describe the new site as a government-branded convenience layer rather than a structural change to drug pricing.
Trump linked the rollout to his "Most Favoured Nation" pricing policy, which seeks to prevent the U.S. from paying more for prescription drugs than other developed countries. "For years, politicians promised lower prices and failed," Trump said, adding that TrumpRx was designed to deliver savings immediately. He appeared alongside Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, and Joe Gebbia, now serving as director of the National Design Studio.
Some of the advertised prices are striking. The GLP-1 weight-loss drug Wegovy is listed at $149 per month, far below its earlier list price of $1,349. However, ABC News reported that Wegovy's price had already been voluntarily reduced by its manufacturer to $499 in March 2025 and to $199 later in the year following negotiations with the federal government, complicating efforts to isolate savings attributable to TrumpRx itself.
Where the discounts may prove more consequential is fertility treatment, an area with limited insurance coverage. According to TrumpRx listings, cash discounts include:
- Gonal-F: 83%
- Cetrotide: 93%
- Ovidrel: 67%
Health economists say such reductions could lower the total cost of an in-vitro fertilization cycle by about 20% for patients paying out of pocket, a meaningful change for families facing five-figure expenses.
Still, limitations remain. "TrumpRx's offerings are very limited, with fewer than 50 drugs listed," said Rena Conti, an associate professor at Boston University's Questrom School of Business. Patients with comprehensive insurance coverage, she noted, may pay less through their plans and risk losing deductible credit by opting to pay cash.
